

# Perspectives of People With HIV (PWH) 12 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)

TUPEB116

William Valenti,<sup>1</sup> Dima Dandachi,<sup>2</sup> Doug Cunningham,<sup>3</sup> Ricky Hsu,<sup>4</sup> Kaitlin Nguyen,<sup>5</sup> Paula Teichner,<sup>5</sup> Ashley Jean-Louis,<sup>6</sup> Maria Reynolds,<sup>6</sup> David Richardson,<sup>6</sup> Cindy Garris<sup>5</sup>

<sup>1</sup>Trillium Health, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; <sup>2</sup>Division of Infectious Diseases, Department of Medicine, University of Missouri-Columbia, MO, USA; <sup>3</sup>Pueblo Family Physicians, Phoenix, AZ, USA; <sup>4</sup>AHF & NYU Langone Health, New York, NY, USA; <sup>5</sup>ViiV Healthcare, Durham, NC, USA; <sup>6</sup>RTI Health Solutions, Research Triangle Park, NC, USA

Please scan this QR code to access a copy of the poster.



Please scan this QR code to access a plain language summary of the poster.



## Key Takeaways

- In this real-world US study, fewer participants reported fear of HIV status disclosure, adherence anxiety, feeling reminded of HIV status, and feeling stigmatized by HIV treatment 12 months after switching to cabotegravir plus rilpivirine long-acting (CAB+RPV LA) when compared with baseline
- Participants switched to CAB+RPV LA primarily because of feeling tired of taking daily oral therapy and almost all preferred the LA option over daily oral therapy after 12 months
- Most people living with HIV-1 reported increased treatment satisfaction, fewer concerns about CAB+RPV LA treatment, and multiple benefits with more frequent clinic visits at Month 12 compared with baseline


## Introduction

- Cabotegravir (CAB) plus rilpivirine (RPV) is the first complete long-acting (LA) regimen administered monthly or every 2 months recommended by treatment guidelines for the maintenance of virologic suppression<sup>1,2</sup> and has demonstrated non-inferiority to daily oral antiretroviral therapy (ART) in phase 3/3b clinical trials<sup>3-5</sup>
- The less frequent dosing schedule may be of interest to some individuals because of convenience or being a better fit for their lifestyle and may also improve psychological and adherence challenges associated with daily oral ART<sup>6</sup>
- The perspectives of people living with HIV-1 and their experiences with CAB+RPV LA are valuable real-world outcomes that can supplement real-world clinical outcomes, as well as results from clinical trials
- Here we present participant-reported outcomes and perspectives of adults living with HIV-1 at baseline and the Month 12 analysis of BEYOND, one of the first real-world studies evaluating the use of CAB+RPV LA in US healthcare settings

## Methods


- The prospective BEYOND study is a 2-year, observational real-world study of people living with HIV-1 initiating CAB+RPV LA monthly or every 2 months across 27 sites in the United States
- 272 participants completed the Month 12 follow-up, 229 (84%) of whom completed Month 12 surveys within the allotted response window of  $\pm 1$  month (data cutoff date: September 11, 2023)

### BEYOND Study Design




## Results


### Participants' Characteristics and Reasons for Initiating CAB+RPV LA




### Treatment Satisfaction Improved From Baseline to Month 12 With CAB+RPV LA Use




### CAB+RPV LA Was Highly Preferred at Month 12




### Participants Reported Improvements in the Psychological Challenges of HIV Treatment




### Concerns About CAB+RPV LA Treatment Decreased From Baseline to Month 12




### Missed/Skipped Injections and Reasons for Missing/Skipping



### Participants Reported Multiple Benefits With More Frequent Clinic Visits After 12 Months on CAB+RPV LA



### Discontinuations



## Conclusions

- In the BEYOND study, switching to CAB+RPV LA was associated with improvements in psychological challenges related to HIV treatment at Month 12
- People living with HIV-1 reported a strong preference for CAB+RPV LA over daily oral ART, increased treatment satisfaction, fewer barriers to injections, and more opportunities to engage with their HIV care